New labeling will suggest STOPPING bisphosphonates (alendronate, etc) after 3 to 5 years in some patients at low fracture risk
New labeling will suggest STOPPING bisphosphonates (alendronate, etc) after 3 to 5 years in some patients at low fracture risk.
This is a case of labeling catching up with the evidence.
Bisphosphonates persist in the bones for years. So 3 to 5 years is enough for many patients...because benefits seem to last even after treatment is stopped.
Get concise, unbiased advice for effective drug therapy, plus CE/CME
Prescriber's Letter includes:
- 12 issues every year, with brief articles about new meds and guidelines
- 48+ CE courses, including the popular CE-in-the-Letter
- Quick reference drug comparison charts
- Access to the entire archive
Already a subscriber? Log in
Volume pricing available. Get a quote